Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw an uptick in trading volume on Wednesday . 412,206 shares were traded during mid-day trading, an increase of 414% from the previous session’s volume of 80,214 shares.The stock last traded at $4.61 and had previously closed at $4.61.

Several analysts have recently issued reports on the company. FBR & Co set a $20.00 price objective on Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 5th. Maxim Group reissued a “buy” rating and set a $9.00 target price (down previously from $24.00) on shares of Galmed Pharmaceuticals in a research report on Monday, August 1st. Zacks Investment Research downgraded Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 19th. Roth Capital reissued a “buy” rating and set a $6.00 target price on shares of Galmed Pharmaceuticals in a research report on Wednesday, July 6th. Finally, HC Wainwright reissued a “buy” rating on shares of Galmed Pharmaceuticals in a research report on Thursday, June 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $12.35.

The firm’s market cap is $51.51 million. The company’s 50-day moving average is $3.96 and its 200 day moving average is $4.68.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/galmed-pharmaceuticals-ltd-glmd-sees-strong-trading-volume.html

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.04. On average, analysts expect that Galmed Pharmaceuticals Ltd. will post ($1.51) earnings per share for the current fiscal year.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

5 Day Chart for NASDAQ:GLMD

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.